Bristol-Myers Squibb has acquired iPierian, a privately held biopharma company, for $175 million, with the potential for additional development and regulatory milestones totaling $550 million, as well as future royalties on sales.   iPierian focuses on developing treatments for Tauopathies, a class of neurodegenerative diseases associated with the Tau protein in the human brain. With the acquisition, BMS gains full rights to iPierian’s lead asset IPN007, a monoclonal antibody with a promising ne...